Pancreatic cancers recycle resources to fuel their survival and growth, opening up the possibility of new treatments aimed at stopping them from doing so, scientists report.

The centre will focus on ‘targeted protein degradation’ – one of the hottest and most promising areas in drug discovery. Scientists aim to hijack normal process of protein destruction to wipe out cancer proteins that traditional targeted drugs cannot block.

Monte Rosa Therapeutics, a biotechnology company originally formed as a spinout from science at The Institute of Cancer Research, London, partly funded by Cancer Research UK, is now listed on the Nasdaq stock exchange in New York.